Selected article for: "adaptive innate immunity and gene expression"
Author: Elkahloun, Abdel G.; Saavedra, Juan M.
Title: Candesartan could ameliorate the COVID-19 cytokine storm
  • Cord-id: mm47i40r
  • Document date: 2020_8_20
    • ID: mm47i40r
    Snippet: BACKGROUND: Angiotensin receptor blockers (ARBs) reducing inflammation and protecting lung and brain function, could be of therapeutic efficacy in COVID-19 patients. METHODS: Using GSEA, we compared our previous transcriptome analysis of neurons injured by glutamate and treated with the ARB Candesartan (GSE67036) with transcriptional signatures from SARS-CoV-2 infected primary human bronchial epithelial cells (NHBE) and lung postmortem (GSE147507), PBMC and BALF samples (CRA002390) from COVID-19
    Document: BACKGROUND: Angiotensin receptor blockers (ARBs) reducing inflammation and protecting lung and brain function, could be of therapeutic efficacy in COVID-19 patients. METHODS: Using GSEA, we compared our previous transcriptome analysis of neurons injured by glutamate and treated with the ARB Candesartan (GSE67036) with transcriptional signatures from SARS-CoV-2 infected primary human bronchial epithelial cells (NHBE) and lung postmortem (GSE147507), PBMC and BALF samples (CRA002390) from COVID-19 patients. RESULTS: Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan. Gene Ontology analysis revealed expression profiles with greatest significance and enrichment, including proinflammatory cytokine and chemokine activity, the NF-kappa B complex, alterations in innate and adaptive immunity, with many genes participating in the COVID-19 cytokine storm. CONCLUSIONS: There are similar injury mechanisms in SARS-CoV-2 infection and neuronal injury, equally reduced by ARB treatment. This supports the hypothesis of a therapeutic role for ARBs, ameliorating the COVID-19 cytokine storm.

    Search related documents:
    Co phrase search for related documents
    • acute inflammatory response and adaptive innate: 1, 2, 3, 4, 5, 6
    • acute lung injury and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute lung injury and adaptive innate immunity: 1, 2, 3, 4
    • acute phase and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute phase and adaptive innate immunity: 1, 2, 3
    • acute phase and long term complication: 1, 2
    • acute sars infection and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars infection and adaptive innate immunity: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars infection and long term complication: 1